Sugi Predict

Sugi Predict / Compounds / SCHEMBL14945583

SCHEMBL14945583

SCHEMBL14945583

OC[C@H](OC1CCOCC1)c1ccccc1O

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 7/20 0.35
▸ TSHR P16473 1/20 0.34
▸ P4HB P07237 1/20 0.34
▸ SMAD3 P84022 1/20 0.34
▸ ACACA Q13085 8/20 0.33
▸ KAT2B Q92831 1/20 0.33
▸ BAZ2B Q9UIF8 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRB2 P47870 1/20 0.33
▸ PRMT5 O14744 1/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26325733 1.00 ACACB (0.35) ACACBTSHRP4HBSMAD3ACACA
SCHEMBL14945449 0.84 ACACB (0.38) ACACBACACAKAT2BBAZ2B
SCHEMBL14945409 0.84 DPP4 (0.40) ACACBACACAKAT2BBAZ2BPRMT5
SCHEMBL14945457 0.84 ACACB (0.38) ACACBACACAKAT2BBAZ2B
SCHEMBL14945398 0.83 ACACB (0.47) ACACBACACA
SCHEMBL29700513 0.83 ACACB (0.47) ACACBACACA
SCHEMBL29642175 0.83 ACACB (0.47) ACACBACACA
SCHEMBL21816549 0.83 ACACB (0.47) ACACBACACA
SCHEMBL14945397 0.83 ACACB (0.47) ACACBACACA
SCHEMBL14948730 0.82 SYK (0.39) ACACBACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3589636-B1 PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF GILEAD SCIENCES INC (US) 2023-09-13 — — EP disclosed
US-20210024537-A1 PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF GILEAD SCIENCES, INC. 2021-01-28 — — US disclosed
US-10745412-B2 Processes for preparing ACC inhibitors and solid forms thereof GILEAD SCIENCES, INC. (US) 2020-08-18 — — US disclosed
US-20200199147-A1 PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF GILEAD SCIENCES, INC. 2020-06-25 — — US disclosed
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF SCHRÖDINGER, INC. 2020-04-02 — — US disclosed
US-10472374-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2019-11-12 — — US disclosed
EP-3329919-B1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO LLC (US) 2019-11-06 — — EP disclosed
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2019-01-17 — — US disclosed
EP-3329919-A1 ACC INHIBITORS AND USES THEREOF Gilead Apollo, LLC (US) 2018-06-06 — — EP disclosed
US-9944655-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-04-17 — — US disclosed
US-9944655-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-04-17 — — US disclosed
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-10-13 — — US disclosed
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-10-13 — — US disclosed
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2015-07-23 — — US disclosed
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2015-07-23 — — US disclosed
US-8969557-B2 ACC inhibitors and uses thereof Nimbus Apollo, Inc. (US) 2015-03-03 — — US disclosed
US-8969557-B2 ACC inhibitors and uses thereof Nimbus Apollo, Inc. (US) 2015-03-03 — — US disclosed
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — US disclosed
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — US disclosed
WO-2013071169-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ACACB 2/4885TSHR 4633/4885P4HB 2299/4885
US-20210024537-A1 PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF ACACA, ACACB, ACAT2 ACACB 2/4885TSHR 4377/4885P4HB 2558/4885
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ACACB 2/4885TSHR 4633/4885P4HB 2299/4885
US-10472374-B2 ACC inhibitors and uses thereof ACACA, ACACB, ACAT2 ACACB 2/4885TSHR 4633/4885P4HB 2299/4885
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ACACB 2/4885TSHR 4633/4885P4HB 2299/4885
US-10745412-B2 Processes for preparing ACC inhibitors and solid forms thereof ACACA, ACACB, ACAT2 ACACB 2/4885TSHR 4377/4885P4HB 2558/4885
US-20200199147-A1 PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF ACACA, ACACB, ACAT2 ACACB 2/4885TSHR 4377/4885P4HB 2558/4885
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ACACB 2/4885TSHR 4633/4885P4HB 2299/4885
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ACACB 2/4885TSHR 4633/4885P4HB 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.